LR
Larimar Therapeutics, Inc.
LRMR · NASDAQ
$3.79 +0.26% (+$0.01)
1M -9.33%
Market Cap $394.8M
P/E Ratio -
Div. Yield -
ROE 137.39%
Bulios Fair Price
$2.06
45.6% downside
Current Price
$3.79
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LRMR is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
65 /100
Fair P/B 3.10x
P/FCF N/A
P/FFO N/A
Growth
0 /100
Declining Book val. growth 11.04%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 104.42%
ROIC 135.25%
Debt
100 /100
Low Current ratio 4.70x
Debt/Equity 0.04x
Net debt/EBITDA N/A
Stability
48 /100
Moderate EPS volatility 59.01%
Profitable years 0
Beta 0.75x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LRMR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Carole S. Ben-Maimon
Employees
71
Headquarters
Bala Cynwyd
Upcoming events
05 NOV
Earnings
Upcoming earnings report